Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ATM | Q13315 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 2/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 0.77 |
| ▸ | AR | P10275 | 2/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estradiol Benzoate SCHEMBL22049057 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Benzoate SCHEMBL29486378 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Benzoate SCHEMBL18467889 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Benzoate SCHEMBL12187133 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Benzoate SCHEMBL174896 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Benzoate SCHEMBL12180364 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Benzoate SCHEMBL301616 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Benzoate SCHEMBL9320465 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Benzoate SCHEMBL20770923 | 0.99 | ESR1 (0.98) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Benzoate SCHEMBL5885955 | 0.96 | ESR1 (0.93) | ESR1LMNASMN1; SMN2ADORA3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2021252761-A2 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| US-20070259837-A1 | Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-08 | — | — | US | disclosed |
| US-20070259837-A1 | Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | ESR1 3204/4885LMNA 3003/4885SMN1; SMN2 641/4885 |
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | SHBG, CYP19A1, GNRHR | ESR1 4/4885LMNA 388/4885SMN1; SMN2 1675/4885 |
| US-20070259837-A1 | Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy | UTRN, MTPN, NR3C1 | ESR1 2263/4885LMNA 348/4885SMN1; SMN2 100/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | ESR1 3204/4885LMNA 3003/4885SMN1; SMN2 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.